 |
- Home
- Products
- About QI
- Mission Statement
- News
- Publications
- Contact QI
- Resources
- Locating Clinical Trials
- Florida Cancer Institute-New Hope
- National Cancer Institute
- University of South Alabama
- NCBI
- National Alliance of Breast Cancer
- National Breast Cancer Organization
- National Breast Cancer Coalition
- Young Survival Coalition
- The Mayo Clinic
- Cancer Center of John Hopkins
- Sloan Kettering Cancer Center
- Harvard Cancer Center
- Moffitt Cancer Center
- Driving Miss Darby
- Team Up! Against Cancer
Quantum Immumologics (QI) is a privately held biotechnology company dedicated to improving the treatment outcomes and quality of life for cancer patients via the research, development, and commercialization of innovative immunotherapeutic and diagnostic products.
QI's individualized ImmunotherapyTM is the result of years of research by staff at the University of South Alabama, college of Medicine and licensed by the South Alabama Medical Science Foundation. The technology centers on an immunogenic, cancer specific protein named OncoFetal Antigen/Immature Laminin Receptor Protein (OFA/iLRP), a well-conserved, cancer-specific antigen expressed on the cell surface of over 500 cancer lines tested to date.
Following all successful trials and approval by FDA, the company plans to market the treatment, initially in the United States, for the treatment of breast cancer. Studies regarding its use in other types of cancer, as well as a new cancer screening tool are planned.
To view QI's full Company Profile, please click here
